- Report
- January 2026
- 180 Pages
Global
From €4074EUR$4,500USD£3,496GBP
- Report
- September 2026
- 193 Pages
Global
From €3209EUR$3,545USD£2,754GBP
€3566EUR$3,939USD£3,060GBP
- Report
- September 2026
- 196 Pages
Global
From €3209EUR$3,545USD£2,754GBP
€3566EUR$3,939USD£3,060GBP
- Report
- September 2026
- 193 Pages
Global
From €3209EUR$3,545USD£2,754GBP
€3566EUR$3,939USD£3,060GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4065EUR$4,490USD£3,488GBP
- Report
- September 2026
- 375 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 129 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 282 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 272 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 456 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 202 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 144 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 164 Pages
Global
From €5296EUR$5,850USD£4,545GBP
- Report
- September 2026
- 150 Pages
Global
From €3395EUR$3,750USD£2,914GBP
- Report
- July 2026
- 130 Pages
Global
From €4300EUR$4,750USD£3,690GBP

The Artificial Pancreas is a medical device that uses biomaterials to regulate blood glucose levels in people with diabetes. It is composed of a continuous glucose monitor (CGM) and an insulin pump, which are connected to a computer algorithm that automatically adjusts insulin delivery. The Artificial Pancreas is designed to mimic the natural pancreas, which produces insulin in response to changes in blood glucose levels. The device is intended to reduce the burden of diabetes management and improve glycemic control.
The Artificial Pancreas market is growing rapidly, driven by increasing prevalence of diabetes, technological advancements, and increasing awareness of the benefits of the device. The market is expected to be further driven by increasing investments in research and development, and the introduction of new products.
Some of the key players in the Artificial Pancreas market include Medtronic, Johnson & Johnson, Insulet Corporation, Dexcom, Tandem Diabetes Care, and Bigfoot Biomedical. Show Less Read more